Art. -Nr.: HY-173425

STING-IN-15

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

STING-IN-15 is an orally active STING inhibitor, with an IC₅₀ of 116 nM against h-STING and an IC₅₀ of 96.3 nM against m-STING. STING-IN-15 inhibits the STING signaling pathway in cells, reduces the secretion of IFN-β and IP-10, downregulates the expression of ISG15, ISG56 and TNF-α, and suppresses the phosphorylation of TBK1/IRF3. STING-IN-15 alleviates systemic and renal inflammation induced by STING agonists in mice, reduces tissue damage and the expression of interferon pathway genes, and inhibits spontaneous tissue inflammation in mice. STING-IN-15 can be used for the research of acute kidney injury and autoimmune/inflammatory diseases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.04%
CAS. Nr.: 2912492-05-6
Formel: C₂₀H₁₄F₂N₄O₃
Molecular Weight:396.35

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

STING-IN-15 Chemical Structure

CAS. Nr.: 2912492-05-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle TNF Receptor Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

In Vitro

STING-IN-15 (Compound 66) (0.3-3 μM; 1 h pretreatment, 4-24 h stimulation) dose-dependently inhibits the STING signaling pathway in human THP1-Dual cells at concentrations of 0.3, 1, and 3 μM, reducing cytokine secretion, inflammatory gene expression, and downstream protein phosphorylation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

THP1-Dual cells
Concentration:

0.3, 1, 3 μM+ MSA-2 (HY-136927) (10 μM)/cGAMP (HY-12512) (10 μM)
Incubation Time:

1 h
Result:

Reduced the mRNA expression of IFNB and IP-10.

Western Blot Analysis^[1]

Cell Line:

THP1-Dual cells
Concentration:

0.3, 1, 3 μM+ MSA-2 (10 μM)/cGAMP (10 μM)/HT-DNA (2 μM)
Incubation Time:

1 h
Result:

Inhibited TBK1/IRF3 phosphorylation.

Parmacokinetics

Species	Dose	Route	AUC_0-∞	T_1/2	MRT_0-∞	Bioavailability	V_z	CL
Rat^[1]	1 mg/kg	i.v.	196 ng·h/mL	0.33 h	0.38 h	/	2382 mL/kg	88.1 mL/min/kg
Mice^[1]	3 mg/kg	p.o.	74.8 ng·h/mL	3.27 h	7.66 h	12.7 %	/	/

In Vivo

STING-IN-15 (10 mg/kg, i.p., single administration) effectively alleviates systemic and renal inflammation induced by MSA-2 in C57BL/6 mice by inhibiting the expression of downstream cytokines and interferon-stimulated genes^[1].
STING-IN-15 (5 mg/kg; i.p.; once daily for 3 consecutive days) exerts STING-dependent protective effects in C57BL/6J mice, targeting Cisplatin (HY-1739)-induced acute kidney injury, and reduces tissue damage and the expression of interferon pathway genes^[1].
STING-IN-15 (10 mg/kg; i.p.; once daily for 14 consecutive days) effectively suppresses spontaneous tissue inflammation in TREX1^D18N mice and reduces the expression levels of inflammatory cytokines and interferon-stimulated genes in renal and cardiac tissues^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (8-week-old male)^[1]
Dosage:

10 mg/kg
Administration:

i.p.; single dose (1 hour prior to MSA-2 stimulation)
Result:

Significantly suppressed MSA-2-induced elevations in plasma IL-6 and IP-10 levels.
Significantly inhibited MSA-2-induced increases in renal mRNA expression of IL-6, Tnf-α, Cxcl-10, Isg15, and Isg56.

Animal Model:

C57BL/6J (8-week-old male); STING-KO C57BL/6 (8-week-old male)^[1]
Dosage:

5 mg/kg
Administration:

i.p.; daily; 3 consecutive days (first dose 1 hour prior to cisplatin injection)
Result:

Largely prevented cisplatin-induced glomerular injury and interstitial vacuolation in wild-type mice.
Significantly reduced cisplatin-induced increases in renal mRNA expression of Ifn-β, Isg15, Isg56, and Cxcl-10 in wild-type mice.
No protective effects on kidney histology or gene expression were observed in STING-KO mice.

Animal Model:

TREX1 D18N; wild-type control^[1]
Dosage:

10 mg/kg
Administration:

i.p.; daily; 14 consecutive days
Result:

Significantly reduced elevated renal mRNA expression of Il6, Cxcl10, Isg15, Isg56, Ifn-β, and Ccl5 in TREX1 D18N mice.
Significantly reduced elevated cardiac mRNA expression of Il6, Cxcl10, Isg15, Isg56, Ifn-β, and Ccl5 in TREX1 D18N mice.

Chemical Information

CAS. Nr. 2912492-05-6
Appearance Solid
Molecular Weight 396.35
Formel C₂₀H₁₄F₂N₄O₃
Color White to off-white
SMILES

O=C(NC1=CNC2=C1C=C(C=C2)/C=C/CC#N)NC3=CC4=C(C=C3)OC(F)(F)O4
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Immunology

IFI16/204 Promotes Dendritic Cell Activation and Anti-Hepatocellular Carcinoma Efficacy via the STING-TBK1-IRF3 Signalling Pathway. [Abstract]

2026 May 17. PMID: 42144282

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (252.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5230 mL

12.6151 mL

25.2302 mL

5 mM

0.5046 mL

2.5230 mL

5.0460 mL

10 mM

0.2523 mL

1.2615 mL

2.5230 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Shen A, et al. Discovery of Potent STING Inhibitors Bearing a Difluorobenzodioxol Structural Motif as Potent Anti-Inflammatory Agents. J Med Chem. 2025;68(8):8907-8932. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5230 mL	12.6151 mL	25.2302 mL	63.0756 mL
	5 mM	0.5046 mL	2.5230 mL	5.0460 mL	12.6151 mL
	10 mM	0.2523 mL	1.2615 mL	2.5230 mL	6.3076 mL
	15 mM	0.1682 mL	0.8410 mL	1.6820 mL	4.2050 mL
	20 mM	0.1262 mL	0.6308 mL	1.2615 mL	3.1538 mL
	25 mM	0.1009 mL	0.5046 mL	1.0092 mL	2.5230 mL
	30 mM	0.0841 mL	0.4205 mL	0.8410 mL	2.1025 mL
	40 mM	0.0631 mL	0.3154 mL	0.6308 mL	1.5769 mL
	50 mM	0.0505 mL	0.2523 mL	0.5046 mL	1.2615 mL
	60 mM	0.0421 mL	0.2103 mL	0.4205 mL	1.0513 mL
	80 mM	0.0315 mL	0.1577 mL	0.3154 mL	0.7884 mL
	100 mM	0.0252 mL	0.1262 mL	0.2523 mL	0.6308 mL

Keywords

STING-IN-15

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

STING-IN-15

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Small Molecule Immuno-Oncology Compound Library

Differentiation Inducing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Publications Citing Use of MedChemExpress (MCE) STING-IN-15

Alle TNF Receptor Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

STING-IN-15

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Small Molecule Immuno-Oncology Compound Library

Differentiation Inducing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Publications Citing Use of MedChemExpress (MCE) STING-IN-15

Alle TNF Receptor Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

STING-IN-15 Related Classifications

HY-173425 Related Classifications